Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration‐resistant prostate cancer receiving abiraterone acetate: An evidence‐based case report and review of literature

Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration‐resistant prostate cancer receiving abiraterone acetate: An evidence‐based case report and review of literature

Abstract Platelet to lymphocyte ratio (PLR) is a candidate prognostic marker for metastatic castration‐resistant prostate cancer patients receiving abiraterone acetate and evidence demonstrates that a high PLR is associated with poor survival. More studies are required to verify current findings and...

Full description

Bibliographic Details
Main Authors: Oliver E. Yausep, Raksheeth Agarwal, Rifqha Aulina, Anthony E. Wijaya, Ilonka Amaia, Addina W. Moekti, Ikhwan Rinaldi, Agus Rizal A. H. Hamid
Format: Article
Language:English
Published: Wiley 2019-08-01
Series:Clinical Case Reports
Subjects:
abiraterone
lymphocyte
metastatic Castration‐Resistant Prostate Cancer
platelet
platelet to lymphocyte ratio
prostate cancer
Online Access:https://doi.org/10.1002/ccr3.2288
Description
Summary:Abstract Platelet to lymphocyte ratio (PLR) is a candidate prognostic marker for metastatic castration‐resistant prostate cancer patients receiving abiraterone acetate and evidence demonstrates that a high PLR is associated with poor survival. More studies are required to verify current findings and establish a definite cutoff point.
ISSN:2050-0904

Similar Items